Search Results
Panel session Orphan drug licensing and M&A trends Learnings from 2013 and what to expect in 2014
Geller explains licensing
Early access to orphan drugs – the rationale, challenges and options available
Global Pharma and Biotech M&A Trends 2010 - 2015
Rare disease collaboration model - big pharma embraces a new approach to drug development
First-hand Perspective on Value of DIA Marketing Pharmaceuticals 2013
Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
How Many Patients do you Need for a Rare Disease Clinical Trial?
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
Case Study: Business Development / Licensing Success Story
The Evolution of Specialty Pharma and Diagnostics
Planning and Executing a Clinical Study for an Orphan Indication
